uniQure N.V./CSL Limited’s hemophilia B gene therapy Hemgenix’s (etranacogene dezaparvovec) $3.5m price tag could be softened through discounts and value-based agreements (VBAs) intended to parse out risk and enhance accessibility.
Value-Based Agreements On The Cards For UniQure/CSL’s $3.5m Hemophilia B Gene Therapy
On Top Of Up To 30% Discounts
While Hemgenix has courted criticism since its $3.5m price tag was unveiled, a drug pricing expert has told Scrip discounts and value-based agreements could make the therapy more palatable to payers.
